Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Income from Continuing Operations (2016 - 2025)

Altimmune (ALT) has disclosed Income from Continuing Operations for 16 consecutive years, with 19014000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 16.77% to 19014000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 84033000.0, a 18.84% increase, with the full-year FY2024 number at 95107000.0, down 7.53% from a year prior.
  • Income from Continuing Operations was 19014000.0 for Q3 2025 at Altimmune, up from 22146000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5382185.0 in Q4 2021 to a low of 33510000.0 in Q3 2021.
  • A 5-year average of 21473263.16 and a median of 21660000.0 in 2022 define the central range for Income from Continuing Operations.
  • Biggest YoY gain for Income from Continuing Operations was 29.67% in 2022; the steepest drop was 302.44% in 2022.
  • Altimmune's Income from Continuing Operations stood at 5382185.0 in 2021, then tumbled by 302.44% to 21660000.0 in 2022, then crashed by 46.17% to 31661000.0 in 2023, then rose by 26.41% to 23298000.0 in 2024, then increased by 18.39% to 19014000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALT's Income from Continuing Operations are 19014000.0 (Q3 2025), 22146000.0 (Q2 2025), and 19575000.0 (Q1 2025).